19:49 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

Cidara Therapeutics Inc. (NASDAQ:CDTX) reported top-line data from 92 patients with candidemia and/or invasive candidiasis in the modified intent-to-treat (ITT) population of the Phase II STRIVE trial showing that once-weekly 400 mg IV rezafungin (formerly...
01:16 , Mar 30, 2018 |  BC Innovations  |  Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
22:50 , Mar 30, 2017 |  BC Extra  |  Preclinical News

CARB-X reveals first investments

Public-private partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) said it is investing $24 million in 11 early stage biotechs developing new antibiotic classes, nontraditional antimicrobial approaches, and other therapeutics and diagnostics to treat Gram-negative...
02:21 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

CD101 Topical: Phase II RADIANT data

Top-line data from 89 patients with moderate to severe acute vulvovaginal candidiasis in the modified intent-to-treat (ITT) population of the open-label, U.S. Phase II RADIANT trial showed that CD101 topical gel and ointment led to...
23:40 , Feb 21, 2017 |  BC Extra  |  Clinical News

Cidara discontinues CD101 topical for vulvovaginal candidiasis

Cidara Therapeutics Inc. (NASDAQ:CDTX) plummeted $4.50 (38%) to $7.20 on Tuesday after discontinuing development of CD101 topical to treat vulvovaginal candidiasis. Both gel and ointment formulations of the product led to lower clinical and mycological...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....